$DVA

Berkshire Hathaway increased its Alphabet stake, buying about 48.1 million shares in Q2 to reach about 106 million shares worth about $37.76B as of June 30, following a June plan for a $10B Alphabet stock investment. It also raised US homebuilder holdings, including Lennar and a new DR Horton position, after buying Taylor Morrison. Berkshire trimmed positions in Kroger, Nucor, DaVita, exited Constellation Brands, and reduced Bank of America, Ally Financial, and Capital One.

Berkshire Hathaway said it spent about $20B on other equities in Q2, repurchased about $4.5B of its own stock, and held $365.5B cash at midyear. It added to Alphabet (GOOGL) and Delta Air Lines (DAL), and disclosed other 13F changes including trims to Bank of America (BAC) and Kroger (KR).

On Aug. 5, Barclays analyst Andrew Mok raised DaVita’s (DVA) price target to $224 and kept an “Equal Weight” rating, according to Barclays. The article cites a mean target of $230.28, about 27% above the current price, and a Street-high target of $270, implying 48.8% upside.

U.S. nonfarm payrolls fell 23,000 in July, with revisions cutting May and June by 103,000, and unemployment down to 4.1%. CME FedWatch showed September rate-hike odds at 42% vs 58%. Stocks rose: SPY +3.5%, QQQ +4.8%, gold +7.5% weekly. Company moves included COHR +43.5%, PLTR +29%, ZBRA guidance raised, TTD fell ~25%.

DaVita HealthCare Partners (NYSE:DVA) rose about 2.1% premarket after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and long-term growth. The upgrade followed DaVita’s Q2 2026 results: adjusted EPS $4.02 vs $3.92 expected, revenue about $3.55B vs estimates, while guidance stayed unchanged.

July nonfarm payrolls fell 23,000, with government hiring missing forecasts, and unemployment edged down to 4.1%. Revisions cut May and June by 103,000. CME FedWatch showed September rate hike odds at 42%. SPY rose 3.5% and QQQ 4.8% for the week; gold gained 2.4% Friday. Next catalysts include Aug. 12 CPI and earnings from PLTR, ZBRA, AMAT.

DaVita HealthCare Partners (DVA) rose about 2.1% in pre-open trading after TD Cowen upgraded it from Hold to Buy and raised its price target to $220 from $201, citing improving competitive position and MOTheR trial results. The upgrade followed DaVita’s Q2 2026 beat, with adjusted EPS of $4.02 vs $3.92 and revenue of about $3.55B vs forecasts, despite flat guidance.

US stock indices eased after early gains, with crude oil sliding to a 3-week low. WTI fell as reports said the US, Iran and Oman were nearing an interim Strait of Hormuz reopening deal, while Saudi Aramco said Houthi threats have not yet hit Red Sea crude exports. Bloomberg Intelligence projects Q2 earnings up about 23% and AI to drive much of S&P 500 EPS growth; markets price a 55% chance of a 25 bp Fed hike.

Oil prices fell after Axios said the US, Iran and Oman were nearing an interim deal to reopen the Strait of Hormuz. Houthi threats to escalate attacks on Saudi tankers and Trump’s comments added volatility. Bloomberg Intelligence expects Q2 earnings up about 23% and 86% of 387 S&P 500 firms beat estimates. Markets also priced rate-hike odds for the FOMC and ECB.

Stocks rose as strong Q2 earnings expectations supported the S&P 500 hitting a new record high. Bloomberg Intelligence projects Q2 earnings up about 23% and AI spending driving nearly 60% of EPS growth. Of 372 S&P 500 firms reporting, 86% beat estimates, per Bloomberg. The article also cites company movers and rate-hike odds for the FOMC and ECB.